report by BlackRock
Results for ""
Investing Ideas
A Broader Tilt to Value
Value stocks, including those outside the U.S., have cheap valuations and could benefit from an improving economic environment.
Investing Ideas
The Challenge of Low but Rising Rates
A low but rising interest rate environment can be challenging for bonds, but, fortunately, it may benefit higher-yielding bonds.
Investing Ideas
[Webinar] How to thrive in uncertain times
2020 brought unprecedented challenges, but despite the disruptions many have thrived in this environment. Find out how to overcome today’s obstacles and focus on building tomorrow’s success.
Sustainable Investing
2019–2020 Responsible Investing Engagement Report
This piece is approved to use with clients.
The 2019-2020 Responsible Investing Engagement Report chronicles Nuveen's active-ownership initiatives and the outcomes achieved over the past year.
Retirement
Adapting to the changing landscape of income
This piece is approved to use with clients.
Retirement is, for many, the culmination of their life’s work. As their financial advisor, you’ve been helping your clients strategize and plan for that milestone. But what happens if what you’ve been planning for changes right before the goal line? We’re seeing that today in the world of retirement income.
Retirement
A New Way to Calculate Retirement Health Care Costs
We believe viewing retirement health care costs as an annual expense, instead of as a lump sum, makes it easier for retirees to plan for and pay for them.
Sustainable Investing
Influencing for good: 20 years of engagement
This piece is approved to use with clients.
The way investors conduct engagement has transformed. From a niche approach largely confined to mission-orientated investors, engagement is now a mainstream investor activity. The success of the Climate Action 100+ initiative in bringing together investors, representing close to US$40 trillion in assets, shows how far we have come.
Sustainable Investing
ESG Viewpoint – COVID-19 and the pharmaceutical industry
This piece is approved to use with clients.
Public trust in the pharmaceutical industry has eroded. The pandemic provides drug-makers a chance to begin re-building their reputation – but only if they prioritise socially responsible practices.